Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
gptkb:A02BA02
|
| gptkbp:brand |
gptkb:Zantac
Ranitic |
| gptkbp:CASNumber |
gptkb:66357-35-5
|
| gptkbp:chemicalFormula |
C13H22N4O3S
|
| gptkbp:contraindication |
hypersensitivity to ranitidine
|
| gptkbp:discoveredBy |
gptkb:Glaxo_Holdings
|
| gptkbp:eliminationHalfLife |
2-3 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ranitidin
|
| gptkbp:introducedIn |
1981
|
| gptkbp:legalStatus |
withdrawn in many countries
|
| gptkbp:mechanismOfAction |
histamine H2 receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
657298
|
| gptkbp:retired |
NDMA contamination risk
|
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
diarrhea
constipation dizziness fatigue headache |
| gptkbp:UNII |
884KT10YB7
|
| gptkbp:usedFor |
treating gastroesophageal reflux disease
treating ulcers treating Zollinger-Ellison syndrome |
| gptkbp:bfsParent |
gptkb:CHEMBL1487
|
| gptkbp:bfsLayer |
7
|